PDC BIOTECH

pdc-biotech-logo

PDC Biotech GmbH (PDC) is a private biopharmaceutical company developing innovative therapeutics for the treatment of preterm labour and primary dysmenorrhea, two areas of significant unmet medical need and large market potential. The primary focus for the company is the development of a pipeline of products which are antagonists of the receptor for prostaglandin F2รŽยฑ (FP receptor). PDC has licensed exclusive worldwide rights to a family of FP receptor antagonists from Theratechnologies Inc. (www.theratech.com) which include both peptides (compounds composed of at least two amino acids) and peptidomimetics (peptide-like compounds).

#People #Financial #Website #More

PDC BIOTECH

Industry:
Biotechnology Health Care Therapeutics

Founded:
2008-01-01

Address:
Vienna, Wien, Austria

Country:
Austria

Website Url:
http://www.pdcbiotech.com

Total Employee:
1+

Status:
Active

Contact:
43 1 8900077

Email Addresses:
[email protected]

Total Funding:
5.5 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible GoDaddy DNS Google Google Cloud CloudFront OpenResty Google Adsense Google Cloud Global Multi-Region AdBlock Acceptable Ads


Founder


not_available_image

Diane Kalina

not_available_image

Patricia Griffin

Investors List

edmond-de-rothschild-investment-partners_image

Andera Partners

Andera Partners investment in Series A - PDC Biotech

mig-ag_image

MIG

MIG investment in Series A - PDC Biotech

Official Site Inspections

http://www.pdcbiotech.com

  • Host name: li647-167.members.linode.com
  • IP address: 198.58.118.167
  • Location: Dallas United States
  • Latitude: 32.7787
  • Longitude: -96.8217
  • Metro Code: 623
  • Timezone: America/Chicago
  • Postal: 75270

Loading ...

More informations about "PDC Biotech"

PDS Biotech - Leadership Team

Conn subsequently became a Director in the Process Development department at Covance Biotechnology Services Inc., a contract research and development and drug manufacturing โ€ฆSee details»

PDS Biotechnology Corporation - Crunchbase Company Profile

PDS Biotechnology Corporation is a biopharmaceutical company. It develops immunotherapies for cancer and other infectious diseases. It develops products to prevent and treat cervical, โ€ฆSee details»

PDS Biotech - Investor Relations

Nov 14, 2024 PDS Biotech is committed to developing novel and effective therapies based on the Versamune® platform to save and improve the lives of cancer patients worldwide. We are โ€ฆSee details»

PDS Biotechnology - Overview, News & Similar companies

Jan 22, 2024 PDS Biotechnology contact info: Phone number: (800) 208-3343 Website: www.pdsbiotech.com What does PDS Biotechnology do? PDS Biotechnology Corporation is a โ€ฆSee details»

PDS Biotechnology Company Overview, Contact Details

Aug 24, 2022 Pdsbiotech hired Lars Boesgaard as Chief Financial Officer on Nov 28th '23. PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation โ€ฆSee details»

PDS Biotechnology - LinkedIn

PDS Biotech is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies based on the Versamune® platform, a T-cell activating โ€ฆSee details»

PDS Biotechnology Corporation (PDSB) - Stock Analysis

Dec 13, 2024 Ticker Symbol: PDSB: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: CIK Code: 0001472091: CUSIP Number: 70465T107: ISIN โ€ฆSee details»

PDS Biotech - About

PDS Biotech is committed to developing novel and effective therapies based on the Versamune® platform to save and improve the lives of cancer patients worldwide. We are also committed to โ€ฆSee details»

PDS Biotech Provides Business Update and Reports Second โ€ฆ

PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (โ€œPDS Biotechโ€ or the โ€œCompanyโ€), a late-stage immunotherapy company โ€ฆSee details»

PDS Biotechnology - Craft

PDS Biotechnology has 5 employees across 3 locations and $2.04 m in total funding,. See insights on PDS Biotechnology including office locations, competitors, revenue, financials, โ€ฆSee details»

PDS Biotech Provides Business Update and Reports First Quarter โ€ฆ

May 15, 2024 The press release will be available in the Investor Relations section of the Companyโ€™s website at www.pdsbiotech.com. Recent Developments. Hosted a Key Opinion โ€ฆSee details»

PDS Biotechnology Corp. (PDS Biotechnology Corp.) - ่ฏ็‰ฉ็ฎก็บฟ_ไธ“ โ€ฆ

For more information, please visit www.pdsbiotech.com. Forward Looking StatementsThis communication contains forward-looking statements (including within the meaning of Section โ€ฆSee details»

PDS Biotech Completes $35 Million Financing Agreement Led

Aug 24, 2022 Email: [email protected]. Nicole Jones CG Capital Phone: +1 (404) 736-3838 Email: [email protected]. Tags Biotechnology ONCOLOGY versamune. Related โ€ฆSee details»

CORPORATE OVERVIEW - PDS Biotech

Nasdaq: PDSB Versamune® is designed to induce a robust and targeted anti-tumor response in vivo when administered with a tumor-associated antigen 5 References: Gandhapudi SK, et al. โ€ฆSee details»

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive โ€ฆ

Aug 1, 2024 Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- โ€ฆSee details»

PDS Biotechnology Corporation (PDSB) - Stock Analysis

5 days ago Website https://www.pdsbiotech.com. Full Company Profile. Financial Performance. Financial Statements. Analyst Forecast. According to 3 analysts, the average rating for PDSB โ€ฆSee details»

CORPORATE OVERVIEW - PDS Biotech

Nasdaq: PDSB 3 PDS Biotechโ€™s Versamune®-based immunotherapies promote a powerful in vivo tumor-specific CD8+ killer T-cell response Generate a strong CD8+ T-cell memory response โ€ฆSee details»

Nominating and Corporate Governance Committee Charter

Title: Microsoft Word - Nominating and Corporate Governance Committee Charter (for distribution to the committee 4-28-16).doc Created Date: 20190626130412ZSee details»

PDS Biotech Announces Presentation of Preliminary PDS0101 โ€ฆ

FLORHAM PARK, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of โ€ฆSee details»

linkstock.net © 2022. All rights reserved